TIKOMED successfully closed fundraising of 8 Million Euros
Viken – 8th February 2019 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced its successful completion of the company’s latest fundraising of 8 Million Euros to support the ongoing clinical development program for both the ILB® program and the IBSOLVMIR® program. TIKOMED is developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases (ILB® program) and an infusion product for improving outcomes in cell therapies (IBSOLVMIR® program). “I’m delighted that we have successfully completed our latest fundraising, which